Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07673107 · ClinicalTrials.gov registry record · Phase 2
Study of AGN-151607-DP to Assess Adverse Events and Change in Disease Activity in Adult Participants With Upper Limb Essential Tremor
A Phase 2 study, sponsored by AbbVie.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 94
- Enrollment target
NCT07673107 is a Phase 2 study that is actively recruiting participants, run by AbbVie. The registered enrollment target is 94 participants.
The verdict
NCT07673107, a Phase 2 study, is actively recruiting participants, sponsored by AbbVie.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 94 participants
- Enrollment target
Study Summary
Upper limb essential tremor (UL ET) is a movement disorder characterized by postural and/or kinetic tremor. It can cause difficulty with everyday tasks such as writing, pouring, and eating. This study will assess if AGN-151607-DP is safe and effective by assessing adverse events and change in disease activity in adult participants with UL ET. AGN-151607-DP is an investigational drug being developed to treat UL ET. Participants will be randomly placed in treatment groups to receive either AGN151607-DP or matching placebo. Approximately 94 adult participants with upper limb essential tremor will be enrolled in approximately 40 sites in the United States/Canada. Participants will receive intramuscular injections of AGN-151607-DP or matching placebo. Duration of the study is approximately 72 weeks. The effect of the treatment will be checked by completion of questionnaires and side effects will be monitored by medical assessments.
Interventions
- DRUG AGN-151607-DP
- DRUG Placebo for AGN-151607-DP
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 94 participants |
| Start Date | 2026-06-18 |
| Est. Completion | 2028-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07673107
The ClinicalTrials.gov registry entry for NCT07673107 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 94 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which AGN-151607-DP is the first listed.
NCT07673107 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07673107 about?
NCT07673107 is a clinical study titled "Study of AGN-151607-DP to Assess Adverse Events and Change in Disease Activity in Adult Participants With Upper Limb Essential Tremor". Upper limb essential tremor (UL ET) is a movement disorder characterized by postural and/or kinetic tremor. It can cause difficulty with everyday tasks such as writing, pouring, and eating. This study will assess if AGN-151607-DP is safe and effective by assessing adverse events and change in diseas...
What is the current status of trial NCT07673107?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 94 participants. The study started on 2026-06-18. Estimated completion is 2028-11.
What interventions are being tested in trial NCT07673107?
The interventions under investigation include: AGN-151607-DP (DRUG), Placebo for AGN-151607-DP (DRUG).
Who is sponsoring clinical trial NCT07673107?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.